Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]Fluciclovine and [18F]FLT PET/CT in High-Grade Brain Tumors
NCT03276676Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Sep 2018
- Primary completion
- Apr 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial (2 arms), sponsored by University of Utah. Primary endpoint: Count of Patients Showing >25% Reduction in Cerebral Uptake of [18F]FLT and [18F]Fluciclovine. Started Sep 2018; status: terminated.
Beyond the preview
Go deeper on NCT03276676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276676.